| Primary |
| Acute Lymphocytic Leukaemia |
60.7% |
| Acute Myeloid Leukaemia |
28.6% |
| Acute Promyelocytic Leukaemia |
10.7% |
|
| Intussusception |
9.1% |
| Sepsis |
9.1% |
| Thrombocytopenia |
9.1% |
| Weight Decreased |
9.1% |
| Blood Cholesterol Increased |
4.5% |
| Blood Triglycerides Increased |
4.5% |
| Cardiac Failure Congestive |
4.5% |
| Neutropenia |
4.5% |
| Neutrophil Count Decreased |
4.5% |
| Pulmonary Embolism |
4.5% |
| Renal Cell Carcinoma |
4.5% |
| Septic Shock |
4.5% |
| Staphylococcal Infection |
4.5% |
| Stem Cell Transplant |
4.5% |
| Subdural Haematoma |
4.5% |
| Vasogenic Cerebral Oedema |
4.5% |
| Venoocclusive Liver Disease |
4.5% |
| Visual Impairment |
4.5% |
|
| Secondary |
| Acute Myeloid Leukaemia |
40.8% |
| Acute Lymphocytic Leukaemia |
28.7% |
| Product Used For Unknown Indication |
12.8% |
| Myelodysplastic Syndrome |
5.5% |
| Lymphocytic Leukaemia |
2.7% |
| Acute Leukaemia |
1.3% |
| Crohn's Disease |
1.3% |
| Acute Myeloid Leukaemia Recurrent |
0.8% |
| Hepatic Function Abnormal |
0.8% |
| Primary Central Nervous System Lymphoma |
0.7% |
| Antiemetic Supportive Care |
0.6% |
| Prophylaxis |
0.6% |
| Aplasia |
0.5% |
| Hypertension |
0.5% |
| Acute Lymphocytic Leukaemia Recurrent |
0.4% |
| Acute Myeloid Leukemia |
0.4% |
| Diffuse Large B-cell Lymphoma |
0.4% |
| Chemotherapy |
0.3% |
| Hyperthermia |
0.3% |
| Infection |
0.3% |
|
| Neutropenia |
11.8% |
| Caecitis |
8.6% |
| Vasculitis Cerebral |
8.6% |
| Sepsis |
6.5% |
| Skin Exfoliation |
6.5% |
| Thrombocytopenia |
6.5% |
| Febrile Bone Marrow Aplasia |
5.4% |
| Neutropenic Sepsis |
5.4% |
| Cardiac Failure |
4.3% |
| Convulsion |
4.3% |
| Restrictive Cardiomyopathy |
4.3% |
| White Blood Cell Count Decreased |
4.3% |
| Cytolytic Hepatitis |
3.2% |
| Hyponatraemia |
3.2% |
| Pancytopenia |
3.2% |
| Renal Failure Acute |
3.2% |
| Shock Haemorrhagic |
3.2% |
| Thyrotoxic Crisis |
3.2% |
| Anaemia |
2.2% |
| Bronchopulmonary Aspergillosis |
2.2% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
21.4% |
| Neoplasm Malignant |
17.9% |
| Product Used For Unknown Indication |
13.1% |
| Pneumonia Legionella |
8.9% |
| Acute Myeloid Leukaemia Recurrent |
8.3% |
| Prophylaxis |
8.3% |
| Gastritis |
3.0% |
| Antifungal Prophylaxis |
2.4% |
| Bone Marrow Transplant |
2.4% |
| Infection |
2.4% |
| Infection Prophylaxis |
1.8% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.8% |
| Acute Lymphocytic Leukaemia |
1.2% |
| Acute Promyelocytic Leukaemia |
1.2% |
| Bone Marrow Conditioning Regimen |
1.2% |
| Febrile Neutropenia |
1.2% |
| Oral Herpes |
1.2% |
| Prophylaxis Against Graft Versus Host Disease |
1.2% |
| Chemotherapy |
0.6% |
| Drug Use For Unknown Indication |
0.6% |
|
| Purpura |
14.7% |
| White Blood Cell Count Decreased |
14.7% |
| Sepsis |
11.8% |
| Acute Generalised Exanthematous Pustulosis |
5.9% |
| Myelodysplastic Syndrome |
5.9% |
| White Blood Cell Count Increased |
5.9% |
| Aborted Pregnancy |
2.9% |
| Cardiac Failure |
2.9% |
| Conjunctivitis |
2.9% |
| Cytolytic Hepatitis |
2.9% |
| Dialysis |
2.9% |
| Disease Progression |
2.9% |
| Enterocolitis Haemorrhagic |
2.9% |
| Graft Versus Host Disease |
2.9% |
| Grand Mal Convulsion |
2.9% |
| Infection |
2.9% |
| Muscular Weakness |
2.9% |
| Nausea |
2.9% |
| Pneumatosis Intestinalis |
2.9% |
| Pyrexia |
2.9% |
|
